Vasoconstrictors and nitrovasodilators reciprocally regulate the Na+-K+-2Clminus cotransporter in rat aorta

Fatma Akar1, Elizabeth Skinner1,2, Janet D. Klein1, Madhumita Jena1, Richard J. Paul3, and W. Charles O'Neill1,4

1 Renal Division, Department of Medicine, 4 Department of Physiology, and 2 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322; and 3 Department of Molecular and Cellular Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Little is known about the function and regulation of the Na+-K+-2Cl- cotransporter NKCC1 in vascular smooth muscle. The activity of NKCC1 was measured as the bumetanide-sensitive efflux of 86Rb+ from intact smooth muscle of the rat aorta. Hypertonic shrinkage (440 mosmol/kgH2O) rapidly doubled cotransporter activity, consistent with its volume-regulatory function. NKCC1 was also acutely activated by the vasoconstrictors ANG II (52%), phenylephrine (50%), endothelin (53%), and 30 mM KCl (54%). Both nitric oxide and nitroprusside inhibited basal NKCC1 activity (39 and 34%, respectively), and nitroprusside completely reversed the stimulation by phenylephrine. The phosphorylation of NKCC1 was increased by hypertonic shrinkage, phenylephrine, and KCl and was reduced by nitroprusside. The inhibition of NKCC1 significantly reduced the contraction of rat aorta induced by phenylephrine (63% at 10 nM, 26% at 30 nM) but not by KCl. We conclude that the Na+-K+-2Cl- cotransporter in vascular smooth muscle is reciprocally regulated by vasoconstrictors and nitrovasodilators and contributes to smooth muscle contraction, indicating that alterations in NKCC1 could influence vascular smooth muscle tone in vivo.

sodium-potassium-chloride cotransport; vascular smooth muscle; contraction; cell chloride; phenylephrine; angiotensin II; endothelin; nitric oxide


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

IN ADDITION TO ION channels, vascular smooth muscle cells (VSMC) possess a variety of ion transporters, the activities of which are influenced by vasoactive substances and growth factors, indicating potential roles in vasoconstriction and smooth muscle hypertrophy. Particular attention has been focused on monovalent cation transporters including the Na+-K+ pump, Na+/H+ antiporter NHE1, and Na+-K+-2Cl- cotransporter NKCC1, in part because they transport Na+ (37). The importance of these transporters may lie in their ability to regulate not only intracellular Na+ concentration ([Na+]) but also intracellular Cl- concentration ([Cl-]), cell volume, and membrane potential. Although various abnormalities in the function of these transporters in essential hypertension and in hypertension models have been described, their significance remains unclear because the findings have generally been limited to nonvascular cells or to VSMC in culture. Because VSMC rapidly lose their contractile phenotype in culture and convert to a proliferative and synthetic phenotype (46), findings for cultured cells may not be indicative of the function and regulation of ion transporters in vivo.

NKCC1 is a prominent transporter in VSMC in culture (29, 31, 32, 42). It is activated by cell shrinkage (29, 30) and is responsible for volume recovery (30), and it is also activated by ANG II both acutely and chronically (2, 32, 48), suggesting a role in smooth muscle contraction and hypertrophy. NKCC1 activity is reduced in cells cultured from aortas of spontaneously hypertensive rats (37, 41). Because of the proliferative phenotype in culture, and particularly because NKCC1 is activated by growth factors and may participate in cell growth, these findings are of questionable relevance to smooth muscle in vivo (33, 34). However, few studies of NKCC1 in intact vascular smooth muscle have been performed. Deth et al. (8) observed a Na+-dependent, Cl--dependent Rb+ influx in rat and rabbit aortas that was inhibited by furosemide, thereby establishing the presence of NKCC1 in intact smooth muscle. Furosemide reduced both the Ca2+ and contractile responses to phenylephrine in this study and has been shown to inhibit smooth muscle contraction in other studies (9, 47), consistent with its vasodilatory action in vivo. However, furosemide is not a specific inhibitor of NKCC1 and can block Cl- transport through other pathways. Davis et al. (6) provided additional evidence for the cotransporter in the rat femoral artery by showing that bumetanide lowered intracellular [Cl-]. This decrease in intracellular [Cl-] was augmented in rats made hypertensive by the administration of deoxycorticosterone and a high-salt diet, suggesting upregulation of NKCC1. Norepinephrine produces an increase in intracellular [Cl-] that is partly blocked by bumetanide (7), indicating activation of NKCC1, but the response of the cotransporter in intact smooth muscle to other vasoconstrictors or to vasodilators has not been examined.

Studies of ion transport in vascular tissue have been limited by technical considerations. NKCC1 activity is usually measured as the influx of 86Rb+, a tracer for K+, but measurements of influx are hampered by problems with trapped extracellular tracer, with normalization (various proportions of cells vs. matrix), and with the large amount of tissue required. NKCC1 activity has also been assayed as changes in intracellular [Cl-] measured with intracellular electrodes (6), but this is technically very demanding and time consuming. Because NKCC1 mediates bidirectional transport, NKCC1 activity can also be measured as the efflux of 86Rb+ (15). Although net transport is inward under physiological conditions, there is a sizable efflux representing Rb+/K+ exchange. The measurement of efflux avoids the problems associated with influx measurements, particularly sample heterogeneity, because results can be normalized to intracellular tracer content. The validity of measuring NKCC1 activity as 86Rb+ efflux was established by previous studies of vascular endothelial cells (15, 28). The efflux of Rb+ in rat aorta has previously been measured and, although somewhat lower than the efflux of K+, showed qualitatively similar responses to norepinephrine and KCl depolarization (43). We have now employed this technique to measure NKCC1 and its regulation by vasoconstrictors and vasodilators in intact smooth muscle from rat aorta. Coupled with the measurement of force generation, this enabled us to demonstrate that the cotransporter has a functional role in vascular smooth muscle.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Tissue preparation. Descending aortas were excised from male Sprague-Dawley rats (200-350 g), dissected free of the adventitia, and opened lengthwise. The endothelium was removed with a cotton swab, after which the vessel was cut into 6-12 pieces that were used immediately for assays.

Cell culture. VSMC were cultured from aortas of Sprague-Dawley rats and were grown in DMEM (high glucose) containing 10% fetal bovine serum. Once the cells reached ~70% confluency, they were serum starved for 72 h in serum-free medium containing insulin, transferrin, and ascorbate (19), with daily medium changes. All studies were performed with monolayers in plastic multiwell plates.

NKCC1 activity. Cotransporter activity was measured as unidirectional K+ efflux as previously described (35), with 86Rb+ as a tracer. The standard isotonic solution was Earle's salts, with HEPES substituted for HCO-3, containing (in mM) 130 NaCl, 5.4 KCl, 1.8 CaCl2, 0.8 MgSO4, 1 NaH2PO4, 5 glucose, and 26 HEPES, pH 7.4. The measured osmolality was 290 mosmol/kgH2O. The solution was made hypertonic by adding 150 mM sucrose. 86RbCl was obtained from DuPont NEN. Bumetanide was a gift from Dr. Peter Sorter (Hoffmann-LaRoche, Nutley, NJ) and was stored as a 100 mM stock solution in DMSO.

Loading of cells with 86Rb+ was accomplished with a 2-h preincubation. Although this did not label the intracellular pool to equilibrium, preliminary studies showed similar responses after loading for 2 and 4 h. For studies requiring preincubation with ANG II, losartan, or lisinopril, these compounds were added to the loading solution. After the loading, the tissue was washed four times over several minutes to remove extracellular radioactivity. Thereafter, medium was removed at 2-min intervals and the tissue was washed with an additional aliquot of medium. The aliquots were combined for counting, and fresh medium was placed on the tissue. The radioactivity in each fraction plus that remaining in the tissue at the end of the assay were measured as Cerenkov radiation in a scintillation counter. These values were used to calculate the amount of 86Rb+ present in the tissue at the start of the assay and at each subsequent time point. Rate coefficients at each time point were calculated by dividing the amount of 86Rb+ in the medium by the amount in the tissue before that time point. Efflux measurements for cultured cells were performed similarly except that medium was changed at 1-min intervals without intervening washes.

In each assay, basal efflux was derived by averaging the last three rate constants before the establishment of test conditions. The new level of efflux was derived by averaging the rate constants at 8 and 10 min afterward (4 and 5 min in cells). Data are presented as means ± SE, and significance was determined by paired t-testing.

Cotransporter phosphorylation. Aortas were prepared as described above and divided lengthwise, and each half was incubated in 1-2 ml of phosphate-free Dulbecco's MEM containing 0.1 mCi/ml of [32P]orthophosphate for 3 h at 37°C in a CO2 incubator. Test substances were added at the end of this incubation. Each half-aorta was homogenized in a ground-glass homogenizer in 250 µl of 250 mM sucrose, 10 mM triethanolamine, 1 µg/ml leupeptin, and 100 µg/ml phenylmethylsulfonyl fluoride (PMSF), pH 7.6. The homogenizer was rinsed with an additional 250 µl, and the two aliquots were combined. SDS was added to a final concentration of 1%, and the mixture was then incubated for 10 min at room temperature. The mixture was passed through an insulin syringe several times and then added to 5 ml of a solution of 2% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) in extraction buffer containing (in mM) 25 Tris · HCl (pH 7.9), 100 sodium pyrophosphate, 100 NaF, 250 NaCl, 10 EGTA, 5 EDTA, 0.2 PMSF, and 0.5 benzamidine, with 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 10 µg/ml soybean trypsin inhibitor. After incubation on ice for 1 h, particulate matter was removed by centrifugation and the supernatant was incubated at 4°C for 12 h with a monoclonal antibody prepared against the Na+-K+-2Cl- cotransporter from human colonic carcinoma cells (T4 antibody; kindly provided by Dr. C. Lytle). Protein G-Sepharose (GIBCO, Grand Island, NY), washed and equilibrated in the 2% CHAPS extraction buffer, was added (50 µl of a 40% suspension per sample) with gentle agitation for 3 h at 4°C. The Sepharose was washed six times with 1% Triton X-100 in extraction buffer and once with K+-free PBS. Bound material was removed by heating the Sepharose in SDS electrophoresis sample buffer and was separated on 7.5% polyacrylamide gels according to the method of Laemmli (17).

Isometric force measurements. Male Sprague-Dawley rats (178-430 g) were anesthetized in a precharged CO2 chamber and killed by cervical dislocation. The aorta was dissected and cleaned of loose fat and connective tissue. A ring of 5 mm was cut from the thoracic aorta; blot weights were 4-5 mg. Rings were mounted between a fixed stainless steel post and one connected to a Kistler-Morse force transducer whose output was monitored with a computer-based data collection system (BioPac). The length between the wires could be adjusted by a micrometer-driven device. Force measurements were then performed as previously described (24). The rings were mounted in a 15-ml organ bath and allowed to equilibrate at 37°C for 1 h, during which the tension was adjusted to 50 mN. This force was chosen because it places the ring at a length within the range for optimal active force generation. Then the aorta was stimulated by the addition of KCl (3 M) to bring the bath concentration to 50 mM. The arteries were then relaxed by exchanging the bathing solution; this contraction-relaxation cycle was repeated until reproducible forces were generated. Then a cumulative concentration-force relation for phenylephrine was generated. Bumetanide (10 µM) was added to the bath, and after 20 min the concentration-force relation was again measured. This experimental protocol for KCl stimulation was repeated in a separate study. After each experiment, ring dimensions and blot weight were measured. Aortic wall thickness (t) was estimated from the formula t = blot weight/(1.05 × length × circumference), and the cross-sectional area (CSA) for force normalization was taken as CSA = 2 × t × length. Studies were performed with a physiological saline solution consisting of (in mM) 118 NaCl, 4.73 KCl, 1.2 MgCl2, 0.026 EDTA, 1.2 KH2PO4, 2.5 CaCl2, 5.5 glucose, and 25 NaH2CO3, which was bubbled with 95% O2-5% CO2 at pH 7.4 and 37°C.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Although normal physiological conditions dictate a net influx of ions through NKCC1, the transporter is bidirectional and exhibits a considerable rate of K+/K+ (Rb+) exchange. Thus cotransporter activity can be measured as Rb+ efflux, which has distinct advantages for intact smooth muscle. Multiple time points for the same segment of aorta can be obtained, substantially reducing the amount of tissue required, and measurement of dry weight or protein or DNA content is not required because the data are normalized to Rb+ content (rate coefficients). A typical assay is shown in Fig. 1. Data are presented as fractions of tracer remaining in the cells (top) and as rate coefficients (bottom). A stable basal efflux was obtained, after which the addition of 50 µM bumetanide, a specific inhibitor of NKCC1, reduced efflux to a new, stable level. Subtraction of the two rate coefficients yields the bumetanide-sensitive flux, which accounts for approximately one-third of the total efflux. The remaining bumetanide-insensitive efflux represents fluxes through K+ channels and K+ leak pathways. This procedure permits the calculation of bumetanide-sensitive efflux for each aortic segment. It has previously been shown that bumetanide-sensitive Rb+ influx in aorta is dependent on extracellular Na+ and Cl- (8), consistent with NKCC1 activity.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Efflux of 86Rb+ from rat aortic smooth muscle. Efflux was measured at 2-min intervals, before and after addition of 50 µM bumetanide (arrows), from rat aorta prepared and loaded with 86Rb+ as described in MATERIALS AND METHODS. Top: fraction of 86Rb+ remaining after each time point. Bottom: fraction of 86Rb+ recovered in medium at each time point expressed as rate coefficient. Results are means ± SE of a representative experiment performed in triplicate.

To measure acute changes in cotransport, parallel assays were performed in the presence and absence of bumetanide (Fig. 2). In this experiment, the addition of 150 mM sucrose to produce hypertonic shrinkage increased total efflux and reduced bumetanide-insensitive efflux, indicating a rapid doubling of cotransporter activity. Cotransporter activity returned to baseline when isotonicity was restored (data not shown). This is consistent with the volume sensitivity of NKCC1 in virtually all cells, including cultured VSMC (29), and indicates that Rb+ efflux provides a reliable assay of NKCC1 activation in intact vascular smooth muscle.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of hypertonic medium on Rb+ efflux in rat aorta. 86Rb+ efflux was measured in isotonic and hypertonic medium (arrows indicate transition). Top: efflux in absence or presence of bumetanide (50 µM). Bottom: bumetanide-sensitive efflux. Results are means ± SE from 3 aortas, each assayed in triplicate.

ANG II (100 nM) significantly increased the efflux of Rb+ (Fig. 3). A portion of the increase was inhibited by 50 µM bumetanide, revealing a transient increase in NKCC1 activity that peaked at 152 ± 11% of control (n = 7, P < 0.001). The increase in bumetanide-insensitive efflux presumably represents the opening of K+ channels. More prolonged incubation with ANG II (performed during loading with 86Rb+) revealed a second, delayed activation of NKCC1 (Fig. 4). There was no stimulation after 1 h of incubation with 100 nM ANG II, but significant stimulation was apparent after 2 h (82 ± 20%; n = 9, P < 0.02) and 4 h (22 ± 3%; n = 3, P < 0.02). Losartan, an antagonist of type 1 ANG II receptors, completely blocked both the acute and delayed stimulation of NKCC1 at a concentration of 10 µM (Fig. 5). There was a small but statistically significant reduction in basal NKCC1 activity (22%) with losartan. However, neither 1 µM saralasin (a peptide antagonist of ANG II) nor 4 µM lisinopril, an inhibitor of ANG II-converting enzyme, reduced basal NKCC1 activity (data not shown). For comparison, efflux in VSMC cultured from rat aorta was also measured. Bumetanide-insensitive efflux was much higher in cells (0.0189 ± 0.0012 min-1) than in aorta, rendering bumetanide-sensitive efflux difficult to measure. However, values for bumetanide-sensitive efflux under basal conditions (0.00228 ± 0.00067-1), after acute ANG II stimulation (0.00423 ± 0.00089-1), and after 2 h of ANG II (0.00544 ± 0.00080-1) were similar to those observed in intact vascular smooth muscle.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of ANG II on Rb+ efflux in rat aorta. Top: efflux of 86Rb+ was measured in absence or presence of bumetanide (50 µM). Bottom: bumetanide-sensitive efflux derived from top data. ANG II (100 nM) was added at time indicated (arrows). Results are means ± SE from 7 aortas, each assayed in triplicate.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   Delayed stimulation of Na+-K+-2Cl- cotransporter NKCC1 by ANG II. Aortas were preincubated with (ANG II) or without (control) ANG II (100 nM) for times indicated, after which efflux of 86Rb+ was measured in absence or presence of bumetanide (50 µM). Results are means ± SE from >= 3 aortas, each assayed in triplicate. * P < 0.02 vs. control.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of losartan on bumetanide-sensitive Rb+ efflux in rat aorta. Aortic segments were preincubated for 2 h with (ANG II) or without (basal) ANG II (100 nM) and with (losartan) or without (control) losartan (10 µM), and efflux of 86Rb+ was measured in presence and absence of bumetanide (50 µM). Results are means ± SE of 7 aortas for basal flux and 4 aortas for flux in presence of ANG II, each measurement performed in triplicate. * P < 0.01 vs. basal control; ** P < 0.001 vs. basal control; *** P < 0.001 vs. ANG II control.

NKCC1 activity in rat aorta was also stimulated acutely by 10 µM phenylephrine (50 ± 13%; P < 0.01, n = 8), 50 nM endothelin (53 ± 17%; P < 0.02, n = 6), and 30 mM KCl (54 ± 6%; n = 5, P <0.01) as shown in Fig. 6. For the KCl experiments, KCl was isosmotically substituted for NaCl to avoid any hypertonic stimulation of NKCC1. However, some cell swelling would be expected in this medium, and this swelling would reduce NKCC1 activity. Thus the stimulation of NKCC1 by membrane depolarization may be greater than that achieved in these experiments. The stimulation of Rb+ efflux by extracellular K+ is unlikely to be due to direct enhancement of K+/Rb+ exchange (trans stimulation) by NKCC1 because stimulation was quantitatively similar at 80 mM (not shown) and because raising extracellular K+ concentration ([K+]) does not increase bumetanide-sensitive Rb+ efflux in endothelial cells (28), which lack voltage-sensitive Ca2+ channels (1). As in the case of ANG II, there was a significant increase in bumetanide-insensitive efflux. Unlike the case of ANG II, there was no delayed stimulation by phenylephrine or endothelin (data not shown).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of vasoconstrictors on bumetanide-sensitive Rb+ efflux in rat aorta. Phenylephrine (10 µM), endothelin (50 nM), and KCl were added at time indicated (arrows). Results are means ± SE from 8 (phenylephrine), 6 (endothelin), and 3 aortas (KCl), each assayed in triplicate.

Nitrovasodilators had an opposite effect on NKCC1. Nitric oxide was tested by using 10 µM 2-(N,N-diethylamino)diazenolate-2-oxide (DEA-NO) as a donor. As shown in Fig. 7, bumetanide-sensitive efflux was inhibited 34%. A similar degree of inhibition was observed with 8 µM nitroprusside, with no additional inhibition at higher concentrations of nitroprusside. S-nitroso-N-acetyl-D,L-penicillamine also inhibited NKCC1, but this did not reach statistical significance. The inhibition of NKCC1 was more apparent when aortas were pretreated with phenylephrine, a process akin to relaxation assays of preconstricted vessels. As shown in Fig. 8, nitroprusside (8 µM) completely reversed the stimulation of NKCC1 by phenylephrine (10 µM).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of nitrovasodilators on bumetanide-sensitive Rb+ efflux in rat aorta. Efflux was measured before and after addition (arrow) of 10 µM 2-(N,N-diethylamino)diazenolate-2-oxide (DEA-NO). Inset: mean bumetanide-sensitive efflux before (control) and after (vasodilator) addition of nitrovasodilators from >= 6 aortic segments. SNP, sodium nitroprusside; SNAP, S-nitroso-N-acetyl-D,L-penicillamine. * P < 0.01 vs. control. Error bars, SE.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of SNP on stimulation of Rb+ efflux in rat aorta by phenylephrine (PE). PE (10 µM) and SNP (8 µM) were added at times indicated (arrows). Results are from 1 experiment performed in triplicate and are representative of 3 additional experiments. Inset: composite data from 4 experiments. Solid bar, mean basal efflux (2-6 min); open bar, mean peak PE efflux (10 min); cross-hatched bar, mean efflux at 16 min. Error bars, SE.

In other cells, stimulation of NKCC1 is associated with phosphorylation of the transporter (10, 14, 20). To confirm this relationship in smooth muscle and to provide definitive evidence for NKCC1 in this tissue, NKCC1 was immunoprecipitated from aortic smooth muscle preincubated with [32P]orthophosphate. As shown in Fig. 9, changes in NKCC1 phosphorylation paralleled changes in bumetanide-sensitive Rb+ efflux, with significant stimulation by phenylephrine, KCl, and hypertonicity and inhibition by nitroprusside. These data confirm that the efflux results accurately represent changes in NKCC1 activity.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 9.   Phosphorylation of NKCC1 in vascular smooth muscle. Rat aortas were labeled with [32P]orthophosphate and treated for 5 min with 30 mM KCl, 10 µM PE, or 10 µM SNP or for 15 min in hypertonic medium (150 mM sucrose; HYPER). This was followed by immunoprecipitation of NKCC1 as described in MATERIALS AND METHODS. A: representative autoradiogram. kD, kilodaltons. B: change in phosphorylation, expressed as percentages of concurrent control (isotonic) samples and measured by densitometry. Bars are means ± SE of 3-5 separate experiments.

To determine the functional significance of cotransporter activation by vasoconstrictors, force generation in aortic rings was measured before and after a 20-min incubation with 10 µM bumetanide (Fig. 10). Bumetanide significantly reduced the contractile response to submaximal concentrations of phenylephrine (63 and 26% at 10 and 30 nM, respectively) without altering maximal contraction. This resulted in approximately a doubling of the half-maximal phenylephrine concentration. In contrast, there was no inhibition of contraction by KCl, under which condition bumetanide would not be expected to lower cell volume or intracellular [Cl-].


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 10.   Effect of bumetanide on aortic contraction. Isometric force in aortic rings was measured as described in MATERIALS AND METHODS before () and after (open circle ) 20 min in 10 µM bumetanide. * P < 0.05, ** P < 0.02 vs. force at same concentration of PE in absence of bumetanide. Error bars, SE.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Rb+ efflux from rat aortic smooth muscle was inhibited 30-40% by bumetanide, a highly specific inhibitor of Na+-K+-2Cl- cotransport, indicating the presence of NKCC1 in vascular smooth muscle. Definitive evidence was provided by immunoprecipitation of the phosphorylated cotransporter from the aorta. This extends previous findings by Deth et al. (8) of furosemide-sensitive, Na+- and Cl--dependent Rb+ influx in aortas from rats and rabbits and the findings by Davis et al. (5) that bumetanide decreases intracellular [Cl-] in vascular smooth muscle from the rat femoral artery. The significant stimulation of bumetanide-sensitive efflux in hypertonic medium is further evidence for the Na+-K+-2Cl- cotransporter, which is universally stimulated by cell shrinkage. The present findings and previous studies contradict the recent contention that NKCC1 is present only in cultured smooth muscle cells and not in intact vascular smooth muscle (38). There are two forms of this transporter, encoded by separate genes (11). Because one form (NKCC2) is found only in the apical membrane of the thick ascending limb of Henle in the kidney, it is assumed that NKCC1 is the form present in vascular smooth muscle, and this is consistent with the presence of NKCC1 mRNA in cultured rat aortic smooth muscle cells (38). The inability of Raat et al. (38) to detect NKCC1 mRNA in freshly isolated rat aortic smooth muscle cells is difficult to explain because we observed similar rate coefficients for bumetanide-sensitive efflux in rat aortas and in rat aortic smooth muscle cells in culture.

All vasoconstrictors tested produced a rapid increase in total Rb+ efflux, consistent with previous studies (3, 21-23, 44). Although this had been ascribed to the opening of K+ channels, we find that NKCC1 contributes substantially to this increase, a contribution ranging from 30% (ANG II) to 36% (phenylephrine). That portion of the KCl-induced K+ efflux previously described as Ca2+ independent and swelling independent (21) may in fact be mediated by NKCC1. The stimulation of NKCC1 by KCl, which acts by depolarizing smooth muscle and activating voltage-sensitive Ca2+ channels to raise intracellular [Ca2+], indicates that the stimulation by other vasoconstrictors is a direct effect of increased intracellular [Ca2+] and not an effect of other receptor-mediated actions. In addition to immediate stimulation of NKCC1, ANG II also demonstrated a second, delayed stimulation between 2 and 4 h that was not observed with phenylephrine. This suggests at least two modes of activation of NKCC1 in vascular smooth muscle and is consistent with both immediate and delayed signaling by ANG II in VSMC (40).

NKCC1 is known to be activated by cell shrinkage or a decrease in intracellular [Cl-]. We have previously shown that activation of NKCC1 by Ca2+-mobilizing agonists in endothelial cells is the result of cell shrinkage or loss of Cl- due to the opening of Ca2+-dependent K+ channels and possibly Cl- channels as well (28). This does not appear to be the case in vascular smooth muscle because equivalent stimulation of NKCC1 occurred with KCl (up to 80 mM), which would prevent cell shrinkage and loss of Cl- through K+ and Cl- channels (28). Furthermore, intracellular [Cl-] in rat arterial smooth muscle does not decrease and actually increases in the presence of phenylephrine (7). Thus stimulation of NKCC1 by vasoconstrictors appears to be a direct effect of raising intracellular [Ca2+] rather than a secondary response to decreased intracellular [Cl-] or cell volume. One possible mechanism may be the recently described link between myosin light chain phosphorylation and NKCC1 activity in endothelial cells (14).

Nitrovasodilators had the opposite effect on NKCC1, inhibiting its basal activity and reversing its stimulation by phenylephrine. The inhibition of NKCC1 by nitroprusside or nitric oxide has not previously been described. cGMP, a mediator of nitrovasodilator effects, stimulates NKCC1 in VSMC in culture (27), which is the opposite of the effect of nitroprusside in rat aorta. However, cGMP is reported to inhibit NKCC1 in cultured endothelial cells (26). Thus the effect of cGMP may vary between cells and with culture conditions. Nitroprusside is reported to lower intracellular [Ca2+] in vascular smooth muscle (22), which would be consistent with the role of intracellular Ca2+ in the stimulation of NKCC1 by vasoconstrictors. Whether nitroprusside has effects on cell volume or intracellular [Cl-] that could inhibit NKCC1 is unknown.

Activation of NKCC1 in other cells depends on phosphorylation (20, 36) and is associated with the phosphorylation of the transporter (10, 14, 20), although it is not known whether the phosphorylation of NKCC1 is required for activation. Consistent with this, we observed changes in the phosphorylation of NKCC1 that paralleled changes in activity. This suggests that vasoconstrictors and nitrovasodilators affect NKCC1 through a common pathway that alters its phosphorylation. The results also indicate that the changes in NKCC1 activity observed in smooth muscle are not due to kinetic effects related to changes in intracellular ion activities.

The opposing effects of vasoconstrictors and vasodilators on NKCC1 suggest that the cotransporter has an important role in smooth muscle contraction, which was confirmed in direct measurements of contraction by phenylephrine. The inhibition by bumetanide was most apparent at low agonist concentrations likely to be physiologically relevant. Bumetanide was recently shown to inhibit the contraction of rat aorta induced by norepinephrine (18), but the response to different doses of agonist and the effect on maximal contraction were not studied. The effect of bumetanide is consistent with the known vasodilatory effect of furosemide in vitro and in vivo (8, 9). However, furosemide is not specific for NKCC1 and can inhibit other Cl- transport pathways. Therefore the effect of bumetanide provides definitive proof that inhibition of NKCC1 can produce vasodilation and indicates that this is the likely mechanism for the vasodilatory effect of furosemide. Vasodilation is not a prominent feature of "loop" diuretics because extensive protein binding limits systemic inhibition of NKCC1. Assuming that 90% of bumetanide is protein bound (4) and that the volume of distribution is 0.068 l/kg (39), a standard dose of 0.015 mg/kg in humans would produce a free plasma concentration of ~60 nM. This is well below the half-inhibitory concentration of ~200 nM (13), but a maximal dose could approach this concentration.

The lack of inhibition of vasoconstriction by KCl indicates possible mechanisms by which NKCC1 promotes contraction. Because the cotransporter would be expected to mediate a net influx under physiological conditions, bumetanide could have several effects in smooth muscle, specifically, a decrease in intracellular [Na+], intracellular [Cl-], or cell volume. The last two would be prevented or significantly reduced by raising external [K+], but the decrease in intracellular [Na+] would not. The fact that the vasodilatory effect of bumetanide is not observed after KCl contraction therefore implicates intracellular [Cl-] or cell volume. It also eliminates the possibility that bumetanide is acting nonspecifically through an effect independent of NKCC1. Bumetanide has been shown to decrease intracellular [Cl-] in vascular smooth muscle (6), indicating a role for NKCC1 in regulating this ion. The activation of NKCC1 by vasoconstrictors may therefore serve to raise intracellular [Cl-], thereby maintaining or increasing the Cl- current that contributes to membrane depolarization and subsequent Ca2+ influx (16, 18, 45). This raises the possibility that alterations in NKCC1 could influence vascular smooth muscle function and blood pressure in vivo.


    ACKNOWLEDGEMENTS

This study was supported by National Institutes of Health Grants HL-47449 and DK-07656.


    FOOTNOTES

F. Akar was supported by the NATO Scientific Fellowship Program of the Scientific and Technical Research Council of Turkey (TUBITAK).

Preliminary accounts of this work have previously been presented in abstract form (12, 25).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests and other correspondence: W. C. O'Neill, Renal Division, Emory Univ. School of Medicine, WMB 338, 1639 Pierce Dr., Atlanta, GA 30322 (E-mail: woneill{at}emory.edu).

Received 28 December 1998; accepted in final form 25 February 1999.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Adams, D. J., J. Barakeh, R. E. Laskey, and C. Van Breemen. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J. 3: 2389-2400, 1989[Abstract/Free Full Text].

2.   Berk, B. C., M. S. Aronow, T. A. Brock, E. J. Cragoe, and M. A. Gimbrone. Angiotensin II-stimulated Na+/H+ exchange in cultured vascular smooth muscle cells. J. Biol. Chem. 262: 5057-5064, 1987[Abstract/Free Full Text].

3.   Bolton, T. B., and L. H. Clapp. The diverse effects of noradrenaline and other stimulants on 86Rb and 42K+ efflux in rabbit and guinea-pig arterial muscle. J. Physiol. (Lond.) 355: 43-63, 1984[Abstract].

4.   Cohen, M. R., E. Hinsch, R. Vergona, J. Ryan, S. J. Kolis, and M. A. Schwartz. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog. J. Pharmacol. Exp. Ther. 197: 697-703, 1976[Abstract].

5.   Davis, J. P., A. R. Chipperfield, and A. A. Harper. Comparison of the electrical properties of arterial smooth muscle in normotensive rats and rats with deoxycorticosterone acetate-salt-induced hypertension: possible involvement of (Na+-K+-Cl-) co-transport. Clin. Sci. (Colch.) 81: 73-78, 1991[Medline].

6.   Davis, J. P., A. R. Chipperfield, and A. A. Harper. Accumulation of intracellular chloride by (Na-K-Cl) co-transport in rat arterial smooth muscle is enhanced in deoxycorticosterone acetate (DOCA)/salt hypertension. J. Mol. Cell. Cardiol. 25: 233-237, 1993[Medline].

7.   Davis, J. P., A. A. Harper, and A. R. Chipperfield. Stimulation of intracellular chloride accumulation by noradrenaline and hence potentiation of its depolarization of rat arterial smooth muscle in vitro. Br. J. Pharmacol. 122: 639-642, 1997[Abstract].

8.   Deth, R. C., R. A. Payne, and D. M. Peecher. Influence of furosemide on rubidium-86 uptake and alpha-adrenergic responsiveness of arterial smooth muscle. Blood Vessels 24: 321-333, 1987[Medline].

9.   Greenberg, S., C. McGowan, J. Xie, and W. R. Summer. Selective pulmonary and venous smooth muscle relaxation by furosemide: a comparison with morphine. J. Pharmacol. Exp. Ther. 270: 1077-1085, 1994[Abstract].

10.   Haas, M., D. McBrayer, and C. Lytle. [Cl-]i-dependent phosphorylation of the Na-K-Cl cotransport protein of dog tracheal epithelial cells. J. Biol. Chem. 270: 28955-28961, 1995[Abstract/Free Full Text].

11.   Hebert, S. C., and S. R. Gullans. Editorial Comment on "The molecular basis of inherited hypokalemic alkalosis: Bartter's and Gitelman's syndromes." Am. J. Physiol. 271 (Renal Fluid Electrolyte Physiol. 40): F957-F959, 1996[Free Full Text].

12.   Jena, M., J. D. Klein, and W. C. O'Neill. Nitric oxide inhibits Na-K-2Cl cotransporter activity and phosphorylation in vascular smooth muscle via a cGMP-independent mechanism (Abstract). J. Am. Soc. Nephrol. 8: 332a, 1997.

13.   Klein, J. D., and W. C. O'Neill. Effect of bradykinin on Na-K-2Cl cotransport and bumetanide binding in aortic endothelial cells. J. Biol. Chem. 265: 22238-22242, 1990[Abstract/Free Full Text].

14.   Klein, J. D., and W. C. O'Neill. Volume-sensitive myosin phosphorylation in vascular endothelial cells: correlation with Na-K-2Cl cotransport. Am. J. Physiol. 269 (Cell Physiol. 38): C1524-C1531, 1995[Abstract/Free Full Text].

15.   Klein, J. D., P. B. Perry, and W. C. O'Neill. Regulation by cell volume of Na+-K+-2Cl- cotransport in vascular endothelial cells: role of protein phosphorylation. J. Membr. Biol. 132: 243-252, 1993[Medline].

16.   Kreye, V. A. W., and F. W. Ziegler. Anions and vascular smooth muscle function. Adv. Microcirc. 11: 114-133, 1982.

17.   Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970[Medline].

18.   Lamb, F. S., and T. J. Barna. Chloride ion currents contribute functionally to norepinephrine-induced vascular contraction. Am. J. Physiol. 275 (Heart Circ. Physiol. 44): H151-H160, 1998[Abstract/Free Full Text].

19.   Libby, P. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J. Cell. Physiol. 115: 217-223, 1983[Medline].

20.   Lytle, C., and B. Forbush III. The Na-K-Cl cotransport protein of shark rectal gland. II. Regulation by direct phosphorylation. J. Biol. Chem. 267: 25438-25443, 1992[Abstract/Free Full Text].

21.   Magliola, L., and A. W. Jones. Depolarization-stimulated 42K+ efflux in rat aorta is calcium- and cellular volume-dependent. Circ. Res. 61: 1-11, 1987[Abstract].

22.   Magliola, L., and A. W. Jones. Sodium nitroprusside alters Ca2+ flux components and Ca2+-dependent fluxes of K+ and Cl- in rat aorta. J. Physiol. (Lond.) 421: 411-424, 1990[Abstract].

23.   Martin, W., and J. L. Gordon. Differential calcium dependence of contractile responses and 86Rb efflux from the rabbit aorta induced by vasoactive stimuli. J. Cell. Physiol. 115: 46-52, 1983[Medline].

24.   McMahon, E. G., and R. J. Paul. Calcium sensitivity of isometric force in intact and chemically skinned aortas during the development of aldosterone-salt hypertension in the rat. Circ. Res. 56: 427-435, 1985[Abstract].

25.   Naisang, E., S. T. Lamitina, and W. C. O'Neill. Role of the Na-K-2Cl cotransporter in vascular smooth muscle hypertrophy (Abstract). J. Am. Soc. Nephrol. 7: 1539, 1996.

26.   O'Donnell, M. E. Regulation of Na-K-Cl cotransport in endothelial cells by atrial natriuretic factor. Am. J. Physiol. 257 (Cell Physiol. 26): C36-C44, 1989[Abstract/Free Full Text].

27.   O'Donnell, M. E., and N. E. Owen. Role of cyclic GMP in atrial natriuretic factor stimulation of Na+, K+, Cl- cotransport in vascular smooth muscle cells. J. Biol. Chem. 261: 15461-15466, 1986[Abstract/Free Full Text].

28.   O'Neill, W. C., and D. F. Steinberg. Functional coupling of Na+-K+-2Cl- cotransport and Ca2+-dependent K+ channels in vascular endothelial cells. Am. J. Physiol. 269 (Cell Physiol. 38): C267-C274, 1995[Abstract/Free Full Text].

29.   Orlov, S. N., T. J. Resink, J. Bernhardt, and F. R. Buhler. Volume-dependent regulation of sodium and potassium fluxes in cultured vascular smooth muscle cells: dependence on medium osmolality and regulation by signalling systems. J. Membr. Biol. 129: 199-210, 1992[Medline].

30.   Orlov, S. N., J. Tremblay, and P. Hamet. Cell volume in vascular smooth muscle is regulated by bumetanide-sensitive ion transport. Am. J. Physiol. 270 (Cell Physiol. 39): C1388-C1397, 1996[Abstract/Free Full Text].

31.   Owen, N. E. Effect of TPA on ion fluxes and DNA synthesis in vascular smooth muscle cells. J. Cell Biol. 101: 454-459, 1985[Abstract].

32.   Owen, N. E., and K. M. Ridge. Mechanism of angiotensin II stimulation of Na-K-Cl cotransport of vascular smooth muscle cells. Am. J. Physiol. 257 (Cell Physiol. 26): C629-C636, 1989[Abstract/Free Full Text].

33.   Panet, R., M. Markus, and H. Atlan. Bumetanide and furosemide inhibited vascular endothelial cell proliferation. J. Cell. Physiol. 158: 121-127, 1994[Medline].

34.   Paris, S., and J. Pouyssegur. Growth factors activate the bumetanide-sensitive Na+/K+/Cl- cotransport in hamster fibroblasts. J. Biol. Chem. 261: 6177-6183, 1986[Abstract/Free Full Text].

35.   Perry, P. B., and W. C. O'Neill. Swelling-activated K fluxes in vascular endothelial cells: volume regulation via K-Cl cotransport and K channels. Am. J. Physiol. 265 (Cell Physiol. 34): C763-C769, 1993[Abstract/Free Full Text].

36.   Pewitt, E. B., R. S. Hedge, M. Haas, and H. C. Palfrey. The regulation of Na/K/2Cl cotransport and bumetanide binding in avian erythrocytes by protein phosphorylation and dephosphorylation effects of kinase inhibitors and okadaic acid. J. Biol. Chem. 265: 1-10, 1990[Abstract/Free Full Text].

37.   Postnov, Y. V., and S. N. Orlov. Ion transport across plasma membrane in primary hypertension. Physiol. Rev. 65: 904-945, 1985[Free Full Text].

38.   Raat, N. J. H., E. Delpire, C. H. Van Os, and R. J. M. Bindels. Culturing induced expression of basolateral Na+-K+-2Cl- cotransporter BSC2 in proximal tubule, aortic endothelium, and vascular smooth muscle. Pflügers Arch. 431: 458-460, 1996[Medline].

39.   Rane, A., J. P. Villeneuve, W. J. Stone, A. S. Nies, G. R. Wilkinson, and R. A. Branch. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin. Pharmacol. Ther. 24: 199-207, 1978[Medline].

40.   Schelling, P., H. Fischer, and D. Ganten. Angiotensin and cell growth: a link to cardiovascular hypertrophy. J. Hypertens. 9: 3-15, 1991[Medline].

41.   Siffert, W., and R. Dusing. Sodium-proton exchange and primary hypertension. Hypertension 26: 649-655, 1995[Abstract/Free Full Text].

42.   Smith, J. B., and L. Smith. Na+/K+/Cl- cotransport in cultured vascular smooth muscle cells: stimulation by angiotensin II and calcium ionophores, inhibition by cyclic AMP and calmodulin antagonists. J. Membr. Biol. 99: 51-63, 1987[Medline].

43.   Smith, J. M., A. A. Sanchez, and A. W. Jones. Comparison of rubidium-86 and potassium-42 fluxes in rat aorta. Blood Vessels 23: 297-309, 1986[Medline].

44.   Somlyo, A. P., and A. V. Somlyo. Signal transduction and regulation in smooth muscle. Nature 372: 231-236, 1994[Medline].

45.   Takenaka, T., M. Epstein, H. Forster, D. W. Landry, K. Iijima, and M. S. Goligorsky. Attenuation of endothelin effects by a chloride channel inhibitor, indanyloxyacetic acid. Am. J. Physiol. 262 (Renal Fluid Electrolyte Physiol. 31): F799-F806, 1992[Abstract/Free Full Text].

46.   Thyberg, J., U. Hedin, M. Sjolund, L. Palmberg, and B. A. Bottger. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 10: 966-990, 1990[Medline].

47.   Tian, R., F. Andreasen, and C. Aalkjaer. Mechanisms behind the relaxing effect of furosemide on the isolated rabbit ear artery. Pharmacol. Toxicol. 68: 406-410, 1991.

48.   Tseng, H., and B. C. Berk. The Na/K/2Cl cotransporter is increased in hypertrophied vascular smooth muscle cells. J. Biol. Chem. 267: 8161-8167, 1992[Abstract/Free Full Text].


Am J Physiol Cell Physiol 276(6):C1383-C1390
0002-9513/99 $5.00 Copyright © 1999 the American Physiological Society